Clinical Trials Logo

Citation(s)

An Open-Label Study of Aranesp® (Darbepoetin Alfa) Administration Once Every Four Weeks in Anaemic Chronic Kidney Disease (CKD) Subjects

Details for clinical trial NCT00124098